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Neuroblastoma (NB) is the most deadly extra-cranial solid tumour in children
necessitating an urgent need for effective and less toxic treatments. One reason for
the lack of efficacious treatments may be the inability of existing drugs to target
the tumour-initiating or cancer stem cell population responsible for sustaining
tumour growth, metastases and relapse. Here, we describe a strategy to identify
compounds that selectively target patient-derived cancer stem cell-like tumour-
initiating cells (TICs) while sparing normal paediatric stem cells (skin-derived
precursors, SKPs) and characterize two therapeutic candidates. DECA-14 and
rapamycin were identified as NB TIC-selective agents. Both compounds induced
TIC death at nanomolar concentrations in vitro, significantly reduced NB xenograft
tumour weight in vivo, and dramatically decreased self-renewal or tumour-
initiation capacity in treated tumours. These results demonstrate that differential
drug sensitivities between TICs and normal paediatric stem cells can be exploited
to identify novel, patient-specific and potentially less toxic therapies.
INTRODUCTION
Neuroblastoma (NB) is a paediatric cancer hypothesized to
develop from primitive neural crest cells that normally
differentiate to form the sympathetic nervous system (Maris
et al, 2007). Patients with advanced disease are treated with
aggressive multimodal therapy that includes intensive chemo-
therapy, radiation, surgery, bone marrow transplant and
immunotherapy. However, the survival of patients older than
1 year with metastatic disease is less than 40% due to relapse
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and extensivemetastatic disease (Matthay et al, 1999). For those
patients who survive their disease, there is significant morbidity
due to treatment-related toxicities (Laverdiere et al, 2009). The
dismal survival statistics as well as the significant side effects of
available treatments led us to investigate new NB treatments.
Recent studies suggest that many solid tumours contain a
population of cancer stem cells or tumour-initiating cells (TICs)
that fuel tumour growth and seed metastases (reviewed in
Dalerba et al, 2007; Frank et al, 2010; Ward & Dirks, 2007).
While many tumours regress after treatments that target
proliferating tumour cells, durable curesmay be rare if therapeutic
agents do not also eliminate TICs (Graham et al, 2002; Konig et al,
2008). We recently described a highly enriched TIC population
from the bone marrow of patients with often-fatal relapse NB that
forms aggressive metastatic tumours when as few as 10 cells are
orthotopically transplanted into immune compromised mice
(Hansford et al, 2007). These NB TICs have several properties
of cancer stem cells including the expression of neural crest
progenitor cell markers, self-renewal in vitro and in vivo and the
ability to differentiate into cell types characteristic of the primary
NB tumour. The NB TICs were isolated and propagated in serum-
free sphere-forming conditions optimized for neural stem cells
growth and maintenance and are used with minimal in vitro
passaging. Therefore, NB TICs may more closely reflect the cells
from bone marrow metastases as compared to NB cell lines
established in serum and selected for adherent culture. We
hypothesize that drugs that induce the death of NB TICs but
that do not harm normal paediatric progenitor cells may be
inherently less toxic than present therapies. Dermal stem cells,
termed skin-derived progenitors or SKPs, have been isolated
and cultured from neonatal skin and exhibit properties similar
to neural crest stem cells (Biernaskie et al, 2009; Fernandes et al,
2004; Hansford et al, 2007; Toma et al, 2001). Like NB TICs, they
aremaintained as spheres in serum-freemedia, self-renew in vitro,
express neural crest progenitor cell markers and differentiate into
neural crest lineage cells, but are non-tumourigenic. The
availability of two different neural crest-like stem cell populations,
highly enriched TICs from NB and normal non-transformed
paediatric stem cells, provides a powerful tool for drug discovery.
In this study, we developed a high-throughput cell-based
screening assay to identify compounds that are preferentially
active against NB TICs. NB TICs, normal paediatric SKPs and
established NB cell lines grown in serum-free sphere-forming
conditions were tested in parallel against small molecule
libraries. Fifty-one compounds that selectively targeted NB
TICs were identified. Two compounds, DECA-14 and rapamy-
cin, were characterized in greater detail and shown to selectively
inhibit NB TIC survival in vitro and significantly reduce both NB
xenograft tumour volume and self-renewal or tumour-initiating
capacity in vivo.
RESULTS
Small molecule screens identify novel chemotherapeutics
NB TICs cultured from bone marrow metastases of a multiple-
relapse NB patient (NB12) were treated with 4383 compounds
from the LOPAC1280TM compound library, the Prestwick
Chemical Library and the Spectrum Collection. Normal human
paediatric SKP cells (FS90) were tested in parallel as a counter-
screen to identify compounds that are selectively cytotoxic or
cytostatic against NB TICs. Cells were treated with test compound
for 30hours prior to a further 24 hour incubation in the presence of
alamarBlue1 and subsequent fluorometric reading (Fig 1A).
Figure 1B shows primary screen data for the three compound
libraries. Primary hits were defined as the compounds whose
B-scores were shifted by at least three standard deviations
(99.73% confidence interval, indicated by coloured lines) from
the mean of the general sample population. Eighty-seven percent
of primary hits were confirmedwhen compounds were retested in
a 3-point dilution series. Primary hits were then tested against NB
TICs (NB12) or SKPs (FS90) in a 10-point dilution series and cell
survival assessed by alamarBlue1 signal to determine IC50 values.
Selective cytotoxicity against NB TICs was defined as a reduced
IC50 value when compared to treatment of normal stem cells
(SKPs). Based on both primary screen results (B-score shifted
more than three standard deviations from the mean) and
confirmatory tests (greater than three-fold shift in IC50 by
alamarBlue1 assay), we identified 51 compounds that were
selectively cytotoxic or cytostatic against NB TICs and 51
compounds with activity against both NB TICs and normal
non-transformed precursor cells (SKPs) (Fig 1C, Supporting
Information Fig (SI) 1). In addition to known anticancer agents,
we identified several classes of compounds including antihista-
mines, antimicrobials and antimalarial agents as well as specific
antagonists to acetaldehyde dehydrogenase, PKC, NF-kB and
nicotinic acetylcholine receptor subunits (Fig 1D, SI1).
To evaluate the value of screening NB TICs in comparison to
established NB cell lines, we tested the three compound libraries
against an established NB cell line, SMS-KCNR, that had been
derived under adherent growth conditions in the presence of
serum (Reynolds et al, 1986). SMS-KCNR was derived from NB
bone marrow metastases, represents a primitive neuroblast
phenotype and can grow robustly under the same serum-free
neurosphere culture conditions as NB TICs and SKPs. Despite
these similarities, there was only 28.0% overlap in the primary
hits observed with NB TICs and SMS-KCNR cells (Fig 1C).
Unlike the NB TICs used in this study, SMS-KCNR carries an
MYCN amplification. To ensure the differential drug sensitivities
we observed were not due toMYCN amplification, we examined
two established cell lines lackingMYCN amplification (SK-N-AS
and SH-SY5Y). As with SMS-KCNR, SK-N-AS and SH-SY5Y cells
were screened in parallel with NB12 TICs in serum-free
neurosphere culture conditions (SI2A). There was approxi-
mately 50% overlap in the primary hits between the lines
(50.88% SK-N-AS vs. NB12, 50.00% SH-SY5Y vs. NB12, 45.69%
SK-N-AS vs. SH-SY5Y). This is in contrast to a comparison of
TICs from bone marrow metastases of three unfavourable
prognosis NB patients where there was 78% overlap between
NB12 and NB88R2, 81.3% overlap between NB12 and NB122R
and 76.5% overlap between NB122R and NB88R2 (SI2B). Thus,
NB TICs from different patients show greater similarity to each
other regarding drug sensitivity than they do to established NB
cell lines.
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Secondary screens identify compounds selective against TICs
from multiple NB patients
Based on the primary screen B-score values as well as the results
of confirmatory assays evaluated through IC50 values, we
selected 38 compounds for secondary screening. In vitro sphere
formation capacity was used as a surrogate measure of TIC self-
renewal capacity (Reynolds & Rietze, 2005; Singh et al, 2004).
NB TICs from multiple patients (described in SI3) as well as
SKPs from several individuals were tested to determine whether
compounds were generally toxic against NB TICs or whether
effects were patient-specific. Sixteen compounds displayed a
large difference in EC50 values for sphere formation between NB
TICs and SKPs (>50-fold, indicated by  in SI1 and SI4D) and
included compounds such as crinamine (SI4A) and dequalinium
analogue, C-14 linker (DECA-14, Fig 2A). Sixteen compounds
had a modest difference in EC50 values (3-50-fold, indicated by

in SI1 and SI4D) and included compounds such as quinacrine
and parthenolide (SI4B). Six compounds had equal potency on
NB TICs and SKPs (indicated by¼ in SI1 and SI4D). Interest-
ingly, a small number of patient-specific TIC-selective drugs
were identified (colchicine, podophyllotoxin, vincristine and
vinblastine, SI4C).
Dequalinium analogue, C-14 linker potently induces
apoptosis in NB TICs
Dequalinium analogue, C-14 linker (DECA-14) was selected for
more detailed in vitro and in vivo analyses due to its greatly
increased toxicity against NB TICs as compared to SKPs and its
potentially novel mechanism of action. DECA-14 is an analogue
of dequalinium (DECA-10), an antimicrobial agent used in
mouthwashes and throat lozenges. DECA-14 decreased the
alamarBlue1 signal of NB12 TICs by 74% in the primary screen
and affected NB TICs in secondary sphere assays at significantly
lower doses than SKPs with EC50 values for sphere formation of
0.38 nM for NB TICs versus 22.53 nM for SKPs (Fig 2A). SMS-
KCNR are 2.4-fold less sensitive to DECA-14 than NB TICS with
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Figure 1. Primary screen identified NB TIC-selective compounds.
A. NB TICs (NB12), SKPs (FS90) or SMS-KCNR cells were treated in parallel with compounds from LOPAC1280TM library, Prestwick Chemical Library or Spectrum
Collection as described in Materials and Methods.
B. Plot of B-scores from the LOPAC1280TM, Prestwick and Spectrum compound libraries screened against FS90 or NB12 cells. Compounds with B-scores greater
than three standard deviations were considered primary hits. Black line, population mean. Coloured line, three standard deviations from the mean.
C. Venn diagram of confirmed primary hits. Cell selectivity was determined by both primary screen and confirmatory assay results. Hit compounds are listed in
SI1.
D. Confirmed primary hits that preferentially target NB TICs (red) or that have activity against both TICs and SKPs (blue) classified by known or suspected
mechanism of action.
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an EC50 of 0.9 nM for sphere formation while SK-N-AS and
SH-SY5Y cells have a sensitivity similar to SKPs using an
alamarBlue1 assay (SI5). NB TICs treated with DECA-14
exhibited decreased cell viability within 24 hours as measured
by trypan blue exclusion with the majority of cells dead after
72 hours (Fig 2B). TICs from multiple NB patient bone marrow
metastases (NB12, NB67, NB88R2, NB122R) were equally
susceptible to DECA-14 (Figs 2A and C). DECA-14 treatment
induced apoptosis in NB TICs as determined by the appearance
of fragmented or condensed nuclei (Fig 2D), increased sub-2n
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Figure 2. DECA-14 selectively targeted NB TICs in vitro and induced rapid apoptotic cell death.
A. DECA-14 was 59-fold more potent against NB TICs (EC50¼0.38 nM) than SKPs (EC50¼ 22.5 nM) in sphere formation secondary assays. Points, mean of
4 unique NB TICs or SKPs and 4 independent experiments with SMS-KCNR cells. Bars, SE.
B. NB12 TICs were treated in triplicate with DECA-14 and cell viability measured by trypan blue exclusion.
C. TICs from high-risk NB patients (NB12, NB88R2, NB122R) were treated with 100 nM DECA-14 or DMSO and viable cell number determined. Points, mean of
triplicate experiment. Bars, SE.
D. Condensed and fragmented nuclear morphology was observed in NB12 TICs after 100 nM DECA-14 treatment. Results from a representative experiment are
shown.
E. NB12 TICs were treated with 100 nM DECA-14 or DMSO for the indicated times and DNA content of propidium iodide-stained samples was assessed.
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DNA content (Fig 2E, SI6) and cleaved PARP and cleaved
caspase 7 in DECA-14-treated cells (SI6).
DECA-14 treatment affects genes that regulate mitochondria
electron transport
To gain insight into the mechanism of DECA-14-induced death,
we performed global gene expression analysis comparing NB12,
NB88R2 and NB122R cells treated with 100 nM DECA-14 or
DMSO for 24 hours. RNA samples were analysed on Affymetrix
GeneChip Human Gene 1.0 ST Array. Genes with evidence of
differential expression between DECA-treated and untreated
cells were identified using the LIMMA Bioconductor package
as described in the Methods (Fig 3A). Twenty-four genes
were found to be downregulated in DECA-14-treated cells
(uncorrected p-value< 0.01), while thirty-two genes were found
to be upregulated (uncorrected p-value< 0.01). Four genes,
ND3, ND4, ND5, LOC44055, were most significantly down-
regulated following DECA treatment, while three genes, ND6,
CHAC1, STC2, were most significantly upregulated (BH-
corrected p-value< 0.05). To characterize the differentially
expressed genes further, we conducted a canonical pathway
enrichment analysis using the Ingenuity Software. We found
that oxidative phosphorylation was one of the key pathways
enriched among the downregulated genes, while upregulated
genes participated in a variety of metabolic and signalling
pathways (Figs 3B, C). Semi-quantitative multiplex PCR (SI7)
confirmed alteration of mRNA levels. Four of the seven most
significantly altered genes were mitochondria-encoded subunits
of NADH dehydrogenase, which make up complex I of the
mitochondrial electron transport chain. Inhibition of complex I
can interfere with energy/ATP generation, increase free radical
production and induce apoptotic cell death (Li et al, 2003).
DECA-14 targets NB TICs in vivo
To examine whether DECA-14 was effective against NB TICs in
vivo, we established xenograft tumours by subcutaneous
injection of NB12 cells into NOD/SCID mice. Once tumours
reached 0.5 cm3, animals were treated with intraperitoneal
injections of DECA-14 every other day. Two doses of DECA-14
were tested: 4.5 or 2.5mg/kg. With the higher dose, significant
constipation was noted and as a result, dosing was limited to
10 days. For subsequent experiments, the dose was reduced to
2.5mg/kg DECA-14 for 14 days and mice received supplemental
hydration with daily subcutaneous injection of lactated Ringer’s
solution. Treatment with either dose resulted in significantly
reduced tumour weight relative to vehicle-treated controls (65%
reduction at 4.5mg/kg and 50.6% reduction with 2.5mg/kg)
(Fig 4A). Treated animals had 13% reduced body weight
(20.89 0.32 g for 2.5mg/kg DECA-14-treated animal vs.
24.22 0.48 g for vehicle-treated animal, p< 0.0001). No other
significant toxicities were noted upon necropsy and pathological
examination of liver, lungs, kidney and heart of treated animals.
To determine whether DECA-14 treatment specifically
targeted the self-renewing and tumour-initiating population
in vivo, tumours were dissociated to single cell suspensions and
viable cells were re-cultured to quantify sphere-formation
capacity. DECA-14 treatment of tumours significantly reduced
the percentage of sphere-forming cells suggesting that DECA-14
targeted NB TICs in vivo (Fig 4B). In a separate experiment, we
examined whether cells from DECA-14-treated tumours had a
reduced ability to initiate tumours in vivo. Fifty-thousand viable
dissociated tumour cells were re-transplanted into the inguinal
fat pad of NOD/SCID mice. Cells from three randomly selected
vehicle-treated tumours and two DECA-14-treated tumours
were injected into two recipient NOD/SCID mice per original
tumour. Five of six vehicle-treated tumour cell recipients
developed secondary tumours with a median tumour volume of
287.4 94.67mm3 that developed at a rate similar to those
generated from NB TICs maintained in tissue culture. Only one
of four DECA-14-treated tumour cell recipients developed a
tumour and this was observed at significantly later time points
compared to control-treated tumour cell recipients (Fig 4C).
Unlike NB TIC xenograft tumours, DECA-14 had no effect on
SK-N-AS xenograft tumours. There was no difference in either
tumour weight or the ability of treated tumour-cells to grow in
methylcellulose-containing culture (Figs 4D, E). Thus, DECA-14
treatment significantly reduced both tumour growth and the
tumour-initiating capacity of NB TICs in vivo.
Rapamycin targets NB TICs in vitro
Our successful identification of NB TIC-selective agents from a
collection of drugs and drug-like molecules suggests that that
this system can be used to evaluate additional compounds that
may be selectively toxic against TICs in other tumours. Several
compounds predicted to be active against TICs were either not
bioactive in our libraries or were subsequently found to be
cytotoxic in 96 hour rather than the 54 hour assays used here.
Rapamycin, amammalian target of rapamycin (mTOR) inhibitor
that was not present in our chemical libraries but was found
in subsequent library screening to be cytotoxic in 96 hour assays
(N. G. and D. R. K., unpublished data) has been identified as a
leukaemic stem cell-selective agent (Yilmaz et al, 2006) and is
currently being tested in clinical trials for various solid tumours.
Therefore, we asked whether rapamycin could preferentially
target NB TICs. In the sphere formation assay described above,
rapamycin had little effect on SKPs or SMS-KCNR cells up to
doses of 1mM (Fig 5A). Likewise, rapamycin was not effective
against SK-N-AS or SH-SY5Y cells (SI8A). In contrast, NB TICs
from four patients were sensitive to rapamycin with a calculated
EC50 value of 0.11 nM (Fig 5A). Rapamycin treatment resulted in
a decrease of cell viability as early as 24 hours with maximal
effects detected between 72 and 96 hours (SI8B). Rapamycin
treatment was also associated with decreased proliferation of
NB TICs isolated from multiple patients (Fig 5B). We confirmed
rapamycin activity by examining the phosphorylation of two
proteins in the mTOR signalling pathway, p70S6K and S6
ribosomal protein (S6RP). Both of the proteins were hyperpho-
sphorylated in all NB TICs tested and the activity of the mTOR
pathway, as assessed by phosphorylation of S6RP, was
significantly upregulated in NB TICs as compared to the two
SKPs lines, FS90 and FS99, and SMS-KCNR (Fig 5C), suggesting
that this pathway is constitutively activated in NB TICs. We did
not, however, observe overexpression or hyperphosphorylation
of mTOR or PTEN in NB TICs when compared to SKPs, although
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there was increased phosphorylation of the mTORC2 substrate
Akt at serine 473 (Fig 5C). Phosphorylation of p70S6K and S6RP
was rapidly inhibited by rapamycin (Fig 5C). Rapamycin
treatment induced features of apoptosis in NB12 and NB122R
cells. These included increase in sub-2n DNA content and the
appearance of cleaved PARP (SI8C, D). NB TICs (NB12,
NB88R2, NB122R) infected with lentiviruses encoding shRNAs
to mTOR or the mTOR binding partners raptor or rictor showed
70–80% growth inhibition compared to NB TICs infected with
lentiviruses carrying mock shRNAs to GFP or LacZ (Fig 5D and
data not shown). These data suggest that components of the
mTOR signalling pathway are constitutively and highly active in
NB TICs, and regulate TIC survival.
Rapamycin targets NB TICs in vivo
Like DECA-14, rapamycin was found to be effective against
established xenograft tumours in vivo. Daily rapamycin
treatment reduced tumour weight by 82.6% for NB12 tumours
and 74.0% for NB88 tumours (Fig 6A) while vinblastine, a
chemotherapy used to treat NB, only reduced tumour weight
43.4% relative to vehicle-treated controls. Rapamycin treatment
inhibited the mTOR pathway in xenograft tumours as expected.
In comparison to vehicle-treated tumours, lysates from tumours
treated with rapamycin exhibited a decrease in phosphorylation
of p70S6K (data not shown) and S6RP (Fig 6C). These results
were confirmed by immunohistochemistry of formalin-fixed
tumour sections for phospho-S6RP (Fig 6B). There was also an
increase in ERK1/2 phosphorylation in rapamycin-treated
tumours that is similar to the increase of ERK1/2 phosphoryla-
tion reported in tumour biopsies of patients treated with
RAD001, a rapamycin analogue (Carracedo et al, 2008) (Fig 6C).
To determine whether rapamycin treatment targeted the NB
TICs in vivo, four vehicle-treated tumours as well as four
rapamycin-treated tumours were dissociated and sphere
formation was examined (Fig 6D). Sphere-forming ability was
reduced 7.75-fold in rapamycin-treated tumours demonstrating
that rapamycin targeted the tumour cell population capable of
self-renewal. The results suggest that rapamycin and rapamycin
analogues may be ideal therapeutics for patients whose NB TICs
that are found to be sensitive to this drug in vitro.
DISCUSSION
Current cancer therapies that target proliferating tumour cells
can dramatically reduce tumour bulk but durable cures may
require elimination of TICs that are hypothesized to be
responsible for tumour growth, metastases and relapse. In
the search for compounds that selectively target TICs, we need
to ensure that identified drugs do not affect normal stem cells
with which TICs share many properties. This is particularly
important for paediatric cancers where normal populations of
stem cells are required for proper development. In this paper, we
describe the identification of compounds that are selectively
toxic to NB TICs while sparing non-transformed paediatric stem
cells (SKPs). We chose to screen NB TICs for a number of
reasons. First, NB TICs are primary cells that faithfully model
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Figure 4. DECA-14 selectively targeted NB TICs in vivo.
A. NB12 xenograft tumours were established and treated with vehicle,
4.5mg/kg DECA-14 or 2.5mg/kg DECA-14 as described in Material and
Methods. Point, tumour weight at autopsy. The median for each group is
indicated. , p¼0.0007, and , p¼0.0014 compared to vehicle-treated
control group.
B. Dissociated DECA-14- or vehicle-treated NB12 tumours were plated in
methylcellulose-containing media. Percentage of sphere-forming cells per
total cell number was calculated from duplicate wells after 10 days. ,
p¼ 0.0003 compared to vehicle-treated control group.
C. Kaplan–Meier survival curve for recipient NOD/SCID mice re-injected with
dissociated NB12 tumour cells from control- (black, circle) or 2.5mg/kg
DECA-14-treated (grey, square) tumours. Survival percentage is depicted
on the left axis and individual tumour volume at autopsy is depicted on the
right axis. Wilcoxon: p¼0.0455, Log-Rank: p¼0.0455.
D. SK-N-AS xenograft tumours were established and treated with vehicle or
2.5mg/kg DECA-14 as described in Material and Methods. Point, tumour
weight at autopsy. The median for each group is indicated.
E. Dissociated DECA-14- or vehicle-treated SK-N-AS tumours were plated in
methylcellulose-containing media. Percentage of sphere-forming cells per
total cell number was calculated from duplicate wells after 18 days.
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high-risk NB tumours. NB TICs express markers of NB and
neural crest progenitors and have chromosomal aberrations
typical of NB tumours. Second, NB TICs self-renew extensively
in vitro as spheres similar to NB bone marrow metastases
observed as clusters on bone marrow smears. Screening of
spheroid cell cultures may identify a different spectrum of active
agents than screening of adherent cell lines that were
established and maintained in serum-containing media (Pam-
paloni et al, 2007). The drug sensitivity of NB TICs appears to be
uniquewhen compared to established NB cell lines such as SMS-
KCNR, SH-SY5Y and SK-N-AS (this study, Gheeya et al, 2009).
Third, NBTICs represent a highly enriched population of TICswith
as few as one NB12 cell required to generate a metastatic tumour
that phenocopies human NB in immunodeficient mice (Hansford
et al, 2007, A. McKee and C. Thiele, unpublished observations).
Finally, we were able to screen NB TICs in parallel with non-
transformed neural crest-like stem cells (SKPs) under identical
in vitro conditions to identify NB TIC-selective compounds.
Using a robust and reproducible cell-based high-throughput
assay, we identified compounds that were effective against TICs
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Figure 5. Rapamycin selectively targeted NB TICs in vitro in a patient-specific fashion.
A. Rapamycin targeted NB TICs while having little effect on SKPs or SMS-KCNR cells in sphere formation secondary assays. Points, mean of 4 unique NB TICs,
4 SKPs and 6 independent experiments with SMS-KCNR. Bars, SE.
B. TICs from high-risk NB patients (NB12, NB88R2, NB122R) were treated with 50 nM rapamycin or DMSO and viable cell number determined. Points, mean of
triplicate experiment. Bars, SE.
C. SKPs (FS90, FS99), NB TICs (NB12, NB88R2, NB122R) or SMS-KCNR cells were treated with DMSO () or 50 nM rapamycin (þ) for 1 h. Immunoblots of
rapamycin-treated cell lysates demonstrated decreased phosphorylation of mTOR target proteins, p70S6K and S6RP. Note that Akt as well as mTOR target
proteins are hyperphosphorylated in NB TICs in comparison to SKPs.
D. shRNA knockdown of mTOR, Rictor, or Raptor decreased NB12 cell viability compared to uninfected or mock shRNAs to GFP or LacZ. Points, mean of triplicate
experiment. Bars, SE.
E. qRT-PCR results for mTOR, Rictor and raptor mRNA 72hours post-infection of NB12 TICs with indicated shRNAs.
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from multiple NB patients in vitro and were effective against
established NB xenograft tumours in vivo. We identified several
interesting classes of compounds including several that have not
been predicted for use in NB treatment such as antimalarial
agents, surfactants and a number of specific protein inhibitors.
This parallel screening approach can also be used to evaluate the
effect of selected clinical drugs on NB TICs as we have
demonstrated for rapamycin.
DECA-14 and the related compound dequalinium (DECA-10)
were identified as hits in our primary screen. DECA-10 has been
shown to inhibit the growth and motility of cancer cell lines
in vitro and in vivo (Bodden et al, 1986; Christman et al, 1990;
Galeano et al, 2005; Weiss et al, 1987) and its cytotoxicity may
be mediated through mechanisms that include impairment of
mitochondrial function (Schneider Berlin et al, 1998; Sancho
et al, 2007; Weiss et al, 1987) or interactions with the
mitochondrial F1-ATPase (Zhuo & Allison, 1988) or protein
kinase C (Rotenberg et al, 1990). We found no evidence for an
effect of DECA-14 on PKC signalling in NB TICs. Indeed, the IC50
for PKCa activity inhibition by DECA-14 is 2.6mM (Qin et al,
2000), while the EC50 for NB TIC sphere inhibition by DECA-14
was 0.38 nM. Likewise, growth inhibition of melanoma cancer
cell lines was observed at nanomolar concentrations (Sullivan
et al, 2000). We examined the effects of several known PKC
inhibitors including DECA-10, DECA-14, chelerythrine chloride
and Go¨6976. Only DECA-14 and chelerythrine chloride were
selectively cytotoxic for NB TICs (Fig 2, SI9). Treatment with
DECA-14 did not alter phosphorylation of PKCa/b substrates
(SI9) or p38MAPK, a downstream target of PKC, nor was
expression or phosphorylation of PKCd, a PKC-isoform
implicated in several human cancers, altered over 72 hours of
DECA-14 treatment (K. M. S. and D. R. K., unpublished data).
Gene expression analysis suggests that DECA-14 treatment of
NB TICs induces apoptosis primarily through effects on
mitochondria. The most significantly altered transcripts were
the mitochondrial NADH dehydrogenase subunits that compose
complex I of the mitochondrial electron transport chain. This is
consistent with previous reports showing that DECA-10
preferentially accumulates in the mitochondria of tumour cells
(Weiss et al, 1987) where it induces selective depletion of
mitochondrial DNA (Schneider Berlin et al, 1998). DECA-10 can
cause DNA unwinding and may result in loss of mitochondrial
DNA through inhibition of DNA synthesis (Schneider Berlin
et al, 1998; Wright et al, 1980). We hypothesize that DECA-14 is
selectively taken up by the mitochondria, where it alters
mitochondrial gene transcription of the NADH dehydrogenase
subunit genes ND3, 4, 5 and 6. Inhibition of Complex I function
is known to interfere with ATP generation, increase the
production of reactive oxygen species and induce apoptosis
(Li et al, 2003).
DECA-14 may have use as a therapeutic drug in NB since
nanomolar doses of DECA-14 induced rapid cell death of NB TICs
in vitro and dramatically reduced tumour weight in vivo. DECA-
14 treatment also impaired the ability of NB TICs to form
secondary tumours in vivo suggesting that the TIC population
was targeted in the primary tumour. Furthermore, the minimal
toxicities observed suggest that DECA-14 may be well tolerated
and potentially could be combined with other NB agents.
Using this cell based-screening assay, we have also assessed
the activity of agents known to be effective against other cancer
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Figure 6. Rapamycin significantly inhibited
tumour growth and targeted NB TICs in vivo.
A. NB12 or NB88R2 xenograft tumours were
established and treated with vehicle, vinblastine
or rapamycin as described in Materials and
Methods. Three independent experiments were
conducted. Points, tumour weight at autopsy. The
median for each group is indicated. , p¼0.0305,
, p< 0.0001 when compared to NB12
vehicle-treated control group. , p¼0.0020 when
compared to NB88R2 vehicle-treated control
group.
B. Immunohistochemical staining of control or
rapamycin-treated tumours for phosphorylated
S6RP (brown staining). Scale bar, 200mm.
C. Tumour lysates from individual control- or
rapamycin-treated xenograft tumours were
immunoblotted with indicated antibodies.
D. Dissociated rapamycin-treated tumours were
plated in methylcellulose-containing media and
sphere formation analysed from triplicate wells
after 10 days. , p¼0.0066 when compared to
control-treated tumour cells.
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stem populations. Rapamycin is amacrolide antibiotic originally
characterized as an antifungal and immunosuppressive agent
(Martel et al, 1977; Sehgal et al, 1975) that inhibits mTOR, a
serine/threonine kinase involved in cell growth (reviewed in
(Wullschleger et al, 2006)). In addition to antiproliferative
properties in a variety of human cancer cell lines (Guertin &
Sabatini, 2007), rapamycin has been shown to preferentially
target leukaemic stem cells from PTEN-deficient murine
leukaemias (Yilmaz et al, 2006). The clinical use of rapamycin
has expanded recently with the development of analogues with
improved pharmacology and bioavailability.
Rapamycin inhibited the survival and proliferation of NBTICs
at nanomolar concentrations that did not affect SKPs or SMS-
KCNR cells. Rapamycin has previously been shown to inhibit
proliferation of several NB cell lines at micromolar doses but did
not significantly increase necrotic or apoptotic cell death
(Marimpietri et al, 2007; Misawa et al, 2003). A recent meta-
analysis of NB tumour mRNA expression microarrays suggested
rapamycin as a potential therapeutic compound (De Preter et al,
2009) and primary NB tumours show expression of activated
Akt and mTOR (Johnsen et al, 2008). It was also observed that
rapamycin treatment of xenografted NB tumours significantly
extended animal survival and decreased tumour volume
(Johnsen et al, 2008; Marimpietri et al, 2007). In these studies,
it was suggested that rapamycin exerts its antitumour effects by
inhibiting both angiogenesis and cell proliferation. Our study
suggests that TICs are a clinically relevant target within the bulk
xenograft tumour as tumour weight was decreased 82.6% and
TIC self-renewal capacity was dramatically decreased in vivo in
addition to decreased TIC survival, proliferation and sphere
formation in vitro. These results are the first demonstration that
rapamycin is effective against NB TICs in vivo and that it can act
as a potent and selective tumour cell death inducer, suggesting
that rapamycin or a rapamycin analogue may be a valuable
chemotherapy adjuvant in a subset of NB patients. Based on
preclinical data generated in this study as well as the
observation that a combination of rapamycin and vinblastine
is effective against NB12 xenograft tumours (L. Z. and S. B.,
unpublished data), a multicenter North American phase 1 study
has opened to evaluate rapamycin in combination with
vinblastine for paediatric solid tumours.
Of those compounds identified as having the greatest
selectivity for NB TICs (>10-fold selectivity compared to SKPs),
the majority are known chemotherapeutics including teniposide
and vinblastine. This was surprising since TICs from other
tumours have been shown to be resistant to various chemother-
apeutics and the primary screen was conducted with NB TICs
derived from a heavily-treated, multiple relapse patient (NB12).
These hits were subsequently confirmed with additional patient
TICs. One unique characteristic of NB is that advanced stage
tumours are sensitive to chemotherapy although clinical
progression inevitably occurs (Thiele, 1998). Interestingly,
several of the chemotherapeutics found to be cytotoxic against
NB12 cells were not cytotoxic to NB67 cells (colchicine,
podophyllotoxin, vincristine and vinblastine). NB67 was
isolated from the same patient as NB12 but after a period of
2 years during which the patient received additional treatments.
Thus, NB67 may be representative of TICs with increased drug
resistance. These observations suggest that it may be possible to
use TICs to predict individual patient responses to chemother-
apy or to study molecular mechanisms of relapse and drug
resistance.
This study represents the first chemical screen to compare a
primary human TIC and a normal neural crest-like non-
transformed counterpart. This type of parallel screen has
enormous potential to predict non-tumour-specific cell toxicity
at a very early point in the drug discovery process. Furthermore,
our results highlight the multiple pathways used by NB cells for
survival and proliferation and have identified pathways that
may be relevant for NB therapy. Importantly, we have
demonstrated that NB TICs from multiple patients show more
commonalities with each other than with an established NB cell
line. The availability of a parallel screen with patient TICs and
normal non-transformed precursor cells (SKPs) also has the
potential to identify patient-specific therapies as demonstrated
by the patient-specific response to vinblastine. Finally, we have
demonstrated that the identified compounds affect TIC renewal
both in vitro and in vivo in a solid tumour.
MATERIALS AND METHODS
Cell culture
SKPs (FS89, FS90, FS99, FS105, FS107) were isolated from neonatal
foreskin and cultured in serum-free proliferation media (PM) as
previously described (Biernaskie et al, 2006; Toma et al, 2005)
following ethics approval by The Hospital for Sick Children Research
Ethics Board. SKPs were used between passages 1–5. NB TICs (NB12,
NB67, NB88R2, NB122R) were isolated as previously described
(Hansford et al, 2007). NB TICs were used between passages 3–15.
Tumour samples and bone marrow aspirates were obtained from
consented patients as approved by The Hospital for Sick Children
Research Ethics Board. SMS-KCNR cells were obtained from Dr. Carol
Thiele (NIH) and cultured as spheres in PM. SH-SY5Y and SK-N-AS cells
were cultured in PM.
Compound libraries and small molecules
The LOPAC1280TM library (Sigma), Prestwick Chemical Library1
(Prestwick Chemical, Inc.) and the Spectrum Collection (MicroSource
Discovery Systems, Inc.) which include 4383 biologically-active
molecules, off-patent drugs and natural products, were provided by
the SMART Facility (Samuel Lunenfeld Research Institute, Mt Sinai
Hospital, Toronto, Canada). Compound libraries were dissolved in
DMSO at 10mM using the BioMek FX (Beckman Coulter, Inc.) and re-
aliquotted as 0.1mM aqueous solutions prior to dispensing into the
assay plates. Additional compounds were purchased from Sigma with
the exception of rapamycin (Calbiochem), DECA-14 (Dr. Susan
Rotenberg, CUNY-Queens) and parthenolide (BioMol). Dilutions were
made in DMSO for secondary assays.
Primary screening assay
The Beckman BioMek FX and the Samuel Lunenfeld Research Institute
High-Throughput Screening Robotics platform were used for cell
seeding, treatment and viability assessment. NB TICs (NB12, NB88R2,
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NB122R), SKPs (FS90) and NB cell lines (SMS-KCNR, SK-N-AS,
SH-SY5Y) were cultured to 85% confluency, dissociated and
resuspended in PMþ30% SKPs conditioned media (CM). Three-
thousand cells were seeded in 100ml per well in non-tissue culture-
treated 96-well plates (Corning Life Sciences). Compounds were
immediately added to a final concentration of 5mM (LOPAC1280) or
1mM (Prestwick, Spectrum). These concentrations were chosen to
obtain hit rates in the 1–2% range, as estimated via pilot experiments.
Cells treated with 0.1% DMSO vehicle alone (eight wells/plate) were
used as the negative controls, while media only (eight wells/plate) was
used to determine the assay noise. Ten microlitre of alamarBlue1 was
added to each well after 30 h and incubated an additional 24 h.
Fluorescence intensity was measured using PHERAstar SpectraMax
Plus384 microplate reader (BMG LABTECH) with an excitation filter of
535nm and an emission filter of 590nm.
Assay quality and hit selection
Under these conditions, the alamarBlue1 signal displayed a linear
response with time, background was minimal, and the dynamic range
satisfactory (i.e. >10). For both NB TICs and SKPs, the variability of
alamarBlue1 signals was low, with coefficient of variation values
ranging between 3.5 and 4.5% across the plates, and the dimension-
less, statistical parameters Z0 and Z factors greater than 0.5 (Zhang et
al, 1999), suggesting an excellent assay quality. The results were
normalized to negative controls using the formula 100(signal-noise/
negative control-noise) to obtain cell survival percentage. The results
were subjected to statistical analysis and corrected for systematic
errors using the B-score method (Brideau et al, 2003). Compounds
with a normalized signal 3 standard deviations away from the mean
B score of the sample population were considered hits.
To confirm hits, compounds were cherry-picked from stock library
plates and diluted in water to generate a 3-point, two-fold dilution
series. Cells were seeded, treated with compound and assayed for
alamarBlue1 reduction as above. IC50 curves were then generated for
confirmed hits from a 10-point, two-fold dilution dose curve of each
compound in triplicate.
Sphere-formation assay
Cells were seeded in triplicate in 96-well non-tissue culture-treated
plates at 3000 cells/well (2000 cells/well for NB12) in 50ml
PMþ30% SKPs CM. Compounds were diluted in PMþCM to the
indicated concentrations and immediately added in a volume of 50ml.
Cells were retreated 3 days post-plating and fixed with 4%
paraformaldehyle (Electron Microscopy Sciences) at day 6. Sphere
number was determined manually. Percentage of control sphere
number was calculated as (mean sphere number for treated wells/
mean sphere number of 0.05% DMSO-treated wells)100. EC50
curves were generated using GraphPad Prism software (GraphPad
Software, Inc.).
Cell viability
10,000 cells were seeded in triplicate in 24-well non-tissue culture-
treated plates in 1ml PMþCM containing compounds at indicated
concentrations or 0.05% DMSO. Spheres were collected, dissociated in
trypan blue and viable cells counted. For knockdown experiments, NB
TICs were infected with either mock treatment or lentivirus encoding
shGFP_437, shFRAP1_193, shRaptor_273, shRaptor_275 and shRic-
tor_333 at an MOI of 10. Seventy-two hours post-infection, the virus
was removed and cells were seeded in triplicate at a density of 10,000
per ml in 24-well plates. The remaining cells were used for RNA
isolation to determine the efficiency of knockdown by qRT-PCR. Viable
cell numbers were determined as above.
Nuclear morphology
40,000 NB12 cells were seeded on 5% lysine/2% laminin coated glass
chamber slides (Nunc Lab-Tek). Cells were treated in duplicate with
DMSO, 100nM DECA-14 or 50 nM rapamycin 24 h after plating. At
indicated time points, cells were fixed with 4% paraformaldehyde and
0.5mg/ml Hoechst 33342 (Sigma), washed with PBS and mounted
with Geltol (Thermo Shandon). Nuclei from 15 random fields were
quantified using a 40 objective.
Propidium iodide staining for DNA content
200,000 NB TICs were seeded in 25 cm2 flasks and treated with
DMSO, 100nM DECA-14 or 50 nM rapamycin after 48 h. At indicated
times, cells were collected, washed in PBS and fixed in 70% ethanol.
Fixed cells were treated with RNaseA, stained with propidium iodide
at 37 8C for 1 h and the cellular DNA content analysed with a FACScan
(Becton Dickinson) and FlowJo software (Tree Star, Inc.)
Immunoblotting analyses
200,000 NB TICs were seeded in 25 cm2 flasks. Cells were treated with
DMSO, 100nM DECA-14 or 50 nM rapamycin 48 h post-plating. At
indicated times, cells were collected, washed in cold PBS and lysates
were prepared in NP-40 lysis buffer. Equal amounts of protein were
resolved on polyacrylamide gels and subjected to immunoblotting
with the following antibodies: anti-cleaved human PARP, anti-
phospho-p70S6K (T389), anti-p70S6K, anti-phospho-S6 ribosomal
protein (S235/236), anti-S6RP, anti-phospho-p42/p44 MAPK (T202/
Y204 ERK1/2), anti-ERK1 (Santa Cruz), anti-phospho-p38, anti-p38,
anti-PKC a/b Substrate, anti-phospho-Akt (S473), anti-Akt, anti-g-
tubulin (Sigma) and anti-GAPDH (Ambion). Unless otherwise noted,
primary antibodies were supplied by Cell Signaling Technologies.
HRP-conjugated goat anti-mouse IgG and goat anti-rabbit IgG
secondary antibodies were used.
Microarray and bioinformatics
NB12, NB88R2 and NB122R cells were treated with 100nM DECA-14
or DMSO for 24 h. Cells were collected and lysed in Trizol and RNA
was purified using RNeasy mini kit (Qiagen). RNA samples were
analysed on Affymetrix GeneChip Human Gene 1.0 ST Arrays.
Microarray data are available in the ArrayExpress database (accession
number E-MEXP-2835). The data were background corrected and
normalized using the Robust Multichip Average (RMA) procedure
implemented in the Affymetrix Expression Console software. Gene-
level expression summaries were computed based on all core probes.
Differential gene expression was assessed between the DECA-treated
and untreated cells using the LIMMA Bioconductor package (Smyth,
2004). The F-statistic with Benjamini–Hochberg (BH) multiple
testing correction implemented in the eBayes function was used
to assess the significance of differential expression. Those genes
with BH-corrected p-value <0.05 were considered statistically
significant. Genes that showed evidence for differential expression
based on both uncorrected p-value <0.01 and BH-corrected p-value
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<0.05 were analysed with Ingenuity Pathway Analysis software
(http://www.ingenuity.com) for functional enrichment. Microarray
results were confirmed by multiplex semi-quantitative RT-PCR. cDNA
was prepared using the Superscript First Strand Synthesis System
(Invitrogen) with 2.5mg total RNA and 50ng random hexamer primer.
0.5ml of cDNA was amplified using primers of the specific gene
and that of an internal control (GAPDH or b2-microglobulin) as
detailed in SI7.
In vivo assays of tumourigenicity
Four- to 5-week-old NOD/SCID mice (Charles River Laboratories)
were housed in a facility certified by the Canadian Council of
Animal Care and used for this study according to a protocol
approved by The Hospital for Sick Children Animal Care Committee.
50,000 NB TICs (NB12 or NB88R2) were resuspended in 50ml PM,
mixed 1:1 with Matrigel (BD Biosciences) and immediately injected
subcutaneously into NOD/SCID mice. For SK-N-AS xenograft tumours,
200,000 SK-N-AS cells cultured in PM were resuspended in 20ml PBS,
mixed 1:3 with Matrigel (Trevigen) and injected as above. Tumour
growth was monitored weekly and treatment was begun when
tumour size reached 0.5 cm2. For experiments with DECA-14, mice
were injected intraperitoneally (IP) every other day with DECA-14
(2.5mg/kg, 14 days or 4.5mg/kg, 10 days) or vehicle (0.36% citrate).
Animals treated with 2.5mg/kg DECA-14 received daily subcutaneous
injections of lactated Ringer’s solution. For rapamycin treatment, mice
were injected IP daily for 14 days with rapamycin (3mg/kg, prepared
every other day), vinblastine (0.25mg/kg) or vehicle (0.2% carboxy-
methylcellulose). All mice underwent complete necropsy examination.
A portion of the tumour was lysed by mechanical homogenization in
Loading Buffer. Equal protein amounts were separated on a 10%
polyacrylamide gel and immunoblotted as above. Tumour and organs
were fixed in 10% formalin for 24 h before paraffin embedding and
haematoxylin-and-eosin (H&E) staining. Tumour sections were pre-
pared for immunohistochemical analysis by standard protocols and
stained for phospho-S6RP (1:100, Cell Signaling Technology) as
described by the manufacturer.
Re-isolation of TICs from treated xenograft tumours
Compound- or vehicle-treated tumours were cut into 2mm2 pieces
and enzymatically dissociated with collagenase type XI (1mg/ml in
H2O, Sigma) for 15–45min at 37 8C. Tumour cells were triturated and
filtered through a 40mm cell strainer. To determine the sphere
formation capacity of treated tumours, dissociated cells were plated in
24-well non-tissue culture-treated plates in PMþ CM containing
0.8% methylcellulose (Sigma) and sphere formation was scored after
10 days. To examine the ability of treated tumour to generate
secondary tumour in vivo, 50,000 dissociated tumours cells were
resuspended in 50ml PM, mixed 1:1 with Matrigel (BD Biosciences)
and injected subcutaneously into 5-week-old NOD/SCID mice. Tumour
growth was monitored twice weekly. Animals were sacrificed when
tumour diameter reached approximately 1 cm. Tumour volume upon
autopsy was calculated as 4/3pabc where a, b and c are tumour radii
(Sorensen et al, 2001).
Statistical analyses
Statistical analyses were performed with GraphPad Prism 4.0 using an
unpaired, two-tailed t-test with p<0.05 as the significance cutoff. To
analyse the secondary tumour formation in Fig 4C, the SAS Procedure
PROC LIFETEST was used (SAS v8.02). The time to tumour formation
was determined as the shortest time for tumour formation among
animals injected with the same tumour cells. The Wilcoxon and the
Log-Rank statistics were used to determine whether a statistical
difference exists between the times to tumour occurrence in these two
groups (DECA-14, Control).
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The paper explained
PROBLEM:
Fewer than 40% of patients older than 1 year with high-risk
neuroblastoma (NB) survive due to disease relapse and extensive
metastatic disease. For those patients who survive their disease,
there is significant morbidity due to treatment-related toxicities.
We hypothesize that new therapies are needed that target
cancer stem cell-like tumour initiating cells (TICs) to provide
durable cures for NB. These new therapiesmust not affect normal
stem cells in these young patients.
RESULTS:
Using a high-throughput cell-based screening assay,
we identified compounds that selectively targeted NB TICs
while having little effect on normal paediatric stem cells.
We further characterized two compounds and
demonstrate that dequalinium analogue, C-14 linker (DECA-14)
and rapamycin prevent TIC self-renewal in vitro and
in vivo.
IMPACT:
Both DECA-14 and rapamycin may have potential use in the
treatment of NB. On the basis of this study, a multicenter
North American phase 1 study has opened to evaluate
rapamycin in combination with vinblastine for paediatric solid
tumours.
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